These findings suggest that the luminal A tumor patients harboring the PIK3CA mutations and the FFL(PDGF/FLT1/SHC1) have significantly longer survival than patients harboring PIK3CA mutations in their tumor only. This evidence concerns the gene PIK3CA and neoplasm.